G1 THERAPEUTICS INC's ticker is GTHX and the CUSIP is 3621LQ109. A total of 120 filers reported holding G1 THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 58.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,715 | -99.5% | 3,274 | -98.2% | 0.00% | -100.0% |
| Q2 2022 | $887,000 | +194.7% | 179,472 | +353.2% | 0.00% | +100.0% |
| Q1 2022 | $301,000 | +11.1% | 39,600 | +49.3% | 0.00% | 0.0% |
| Q4 2021 | $271,000 | -66.4% | 26,516 | -55.9% | 0.00% | -50.0% |
| Q3 2021 | $807,000 | +78.1% | 60,133 | +138.7% | 0.00% | +100.0% |
| Q4 2020 | $453,000 | -90.7% | 25,188 | -94.0% | 0.00% | -90.9% |
| Q3 2020 | $4,888,000 | +6.5% | 423,211 | +123.7% | 0.01% | 0.0% |
| Q2 2020 | $4,589,000 | +769.1% | 189,166 | +295.2% | 0.01% | +450.0% |
| Q1 2020 | $528,000 | +15.8% | 47,870 | +139.2% | 0.00% | +100.0% |
| Q3 2019 | $456,000 | +714.3% | 20,015 | +992.5% | 0.00% | – |
| Q2 2019 | $56,000 | +64.7% | 1,832 | -10.2% | 0.00% | – |
| Q1 2019 | $34,000 | +70.0% | 2,039 | +98.3% | 0.00% | – |
| Q4 2018 | $20,000 | -99.5% | 1,028 | -98.6% | 0.00% | -100.0% |
| Q3 2018 | $3,926,000 | +67.7% | 75,076 | +39.4% | 0.01% | +28.6% |
| Q2 2018 | $2,341,000 | – | 53,859 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 1,423,794 | $34,541,000 | 9.18% |
| Burrage Capital Management LLC | 373,876 | $9,070,000 | 6.35% |
| Birchview Capital, LP | 40,000 | $970,000 | 0.59% |
| 361 CAPITAL LLC | 47,325 | $1,148,000 | 0.54% |
| Rhenman & Partners Asset Management AB | 190,000 | $4,609,000 | 0.50% |
| CHI Advisors LLC | 44,000 | $1,067,000 | 0.42% |
| Bellevue Group AG | 721,925 | $17,514,000 | 0.25% |
| Candriam S.C.A. | 870,423 | $21,117,000 | 0.22% |
| Virtus ETF Advisers LLC | 18,991 | $461,000 | 0.22% |
| HHLR ADVISORS, LTD. | 949,431 | $23,033,000 | 0.21% |